Advertisement

Drug Investigation

, Volume 5, Issue 5, pp 285–287 | Cite as

Hyponatraemia in a Patient Treated with Bromocriptine

  • Christine Damase-Michel
  • Eric Sarrail
  • Jean Laens
  • Jean-Louis Montastruc
  • Paul Montastruc
Case Report

Keywords

Vasopressin Bromocriptine Sodium Excretion Quinpirole Dopaminergic Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Begaud B, Evreux J, Jouglard J, Lagier G. Unexpected or toxic drug reaction assessment (Imputation). Actualization of the method used in France. Thérapie 40: 111–118, 1985PubMedGoogle Scholar
  2. Bello-Reuss E, Higashi Y, Kaneda Y. Dopamine decrease fluid reabsorption in straight portions of rabbit proximal tubule. American Journal of Physiology 242: 634–640, 1982Google Scholar
  3. Bogaert M, Buylaert W, Lefebvre R, Willems J. Récepteurs dopaminergiques périphériques. Actualités Pharmacologiques 33: 57–75, 1980Google Scholar
  4. Damase-Michel C, Montastruc JL, Tran MA, Gharib C, Geelen G, et al. Involvement of vasopressin in the cardiovascular effects of quinpirole. European Journal of Pharmacology 184: 179–183, 1990PubMedCrossRefGoogle Scholar
  5. Horrobin DF. Prolactin as a regulator of fluid and electrolyte metabolism in mammals. Federation Proceedings 39: 2567–2570, 1980PubMedGoogle Scholar
  6. Lokhandwala MF, Hedge SS. Cardiovascular dopamine receptors: Role of renal dopamine and dopamine receptors in sodium excretion. Pharmacology and Toxicology 66: 237–243, 1990PubMedCrossRefGoogle Scholar
  7. Marschall AW, Jakobovits AW, Morgan MY. Bromocriptine-associated hyponatraemia in cirrhosis. British Medical Journal 285: 1534, 1982CrossRefGoogle Scholar
  8. McDonald RH, Goldberg LI, McNay JL, Tuttle EP. Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. Journal of Clinical Investigation 43: 1116, 1964PubMedCrossRefGoogle Scholar
  9. Montastruc JL, Montastruc P. Alpha-adrenolytic properties of bromocriptine. Archives Internationales de Pharmacodynamie et de Therapie 260: 83–90, 1982PubMedGoogle Scholar
  10. Moses A, Miller M. Drug induced dilutional hyponatremia. New England Journal of Medicine 5: 1234–1239, 1974CrossRefGoogle Scholar
  11. Nagahama S, Ann HS, Chen Y, Linheimer MD, Oparil S. Role of vasopressin in the cardiovascular effects of LY 171555, a selective D2 receptor agonist; studies in conscious Brattleboro and Long-Evans rats. Journal of Pharmacological and Experimental Therapeutics 242: 143, 1987Google Scholar
  12. Pettinger WA, Umemura S, Smyth D, Jeffries W. Renal α2-adrenoceptors and the adenylate cyclase-cAMP system: biochemical and physiological interactions. American Journal of Physiology 252: 199–208, 1987Google Scholar
  13. Robinson EG, Clifton-Bligh P, Posen S, Morris BJ. The effect of bromocriptine on circulating vasopressin. Clinical Science 63: 367–372, 1982PubMedGoogle Scholar
  14. Seri I. Dopamine and natriuresis mechanism of action and developmental aspects. American Journal of Hypertension 3: 82–86, 1990Google Scholar
  15. Smyth D, Pettinger WA, Umemura S. Renal nerve stimulation causes α1-adrenoceptor mediated sodium retention but no α2-adrenoceptor antagonism of vasopressin. Circulation Research 57: 304–311, 1985PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Christine Damase-Michel
    • 1
  • Eric Sarrail
    • 2
  • Jean Laens
    • 2
  • Jean-Louis Montastruc
    • 1
  • Paul Montastruc
    • 1
  1. 1.Service de Pharmacologie Médicale et Clinique, INSERM U317Centre Midi-Pyrénées de Pharmacovigilance et d’Informations sur le Médicament, Faculté de MédecineToulouseFrance
  2. 2.Centre Hospitalier GénéralTarbesFrance

Personalised recommendations